Ingentium Melanoma

@ingentium_mel

this is a social feed of news compiled by our Cybernetic Curator platform. you can read our news magazine at

boston, ma
Vrijeme pridruživanja: ožujak 2018.

Tweetovi

Blokirali ste korisnika/cu @ingentium_mel

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @ingentium_mel

  1. Spatial reveals insights into the tumour microenvironment

    Poništi
  2. ASCO names refinement of surgical treatment 'Advance of the Year'

    Poništi
  3. New Liquid Biopsy Method IDs Patients Likely to Relapse

    Poništi
  4. 5. velj

    Liquid biopsy independently associated with relapse, study shows

    Poništi
  5. 5. velj

    Shift in treatment modalities associated with improved outcomes in patients with live

    Poništi
  6. 5. velj
    Poništi
  7. 5. velj

    Nail Apparatus Features Good Survival and Functional Outcome

    Poništi
  8. 5. velj

    Study demonstrates liquid biopsy as effective predictor of stage III relapse and treatment

    Poništi
  9. 5. velj
    Poništi
  10. 4. velj
    Poništi
  11. 4. velj

    New type of may better treat , according to UCLA-led study

    Poništi
  12. 4. velj

    First Eastern European experience of isolated limb infusion for in-transit metastatic confined to the limb: Is it still an effective treatment option in the modern era?

    Poništi
  13. 4. velj

    therapy for : how to choose?

    Poništi
  14. 4. velj

    dabrafenib plus trametinib versus placebo in patients with resected, BRAF-mutant, stage III (COMBI-AD): exploratory analyses from a randomised, phase 3 trial.

    Poništi
  15. 3. velj

    WDR74 modulates tumorigenesis and metastasis through the RPL5-MDM2-p53 pathway.

    Poništi
  16. 3. velj

    Targeting CSPG4 for isolation of cell-derived exosomes from body fluids.

    Poništi
  17. 3. velj

    Psychosocial impact of prognostic testing in patients: a controlled prospective clinical observational study.

    Poništi
  18. 3. velj

    Inhibition of BCL2 family members increases the efficacy of copper chelation in BRAFV600E-driven .

    Poništi
  19. 3. velj

    Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist.

    Poništi
  20. 3. velj

    Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated therapy.

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·